Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2020

Open Access 01-12-2020 | Review

Recent sylvatic yellow fever virus transmission in Brazil: the news from an old disease

Authors: Natalia Ingrid Oliveira Silva, Lívia Sacchetto, Izabela Maurício de Rezende, Giliane de Souza Trindade, Angelle Desiree LaBeaud, Benoit de Thoisy, Betânia Paiva Drumond

Published in: Virology Journal | Issue 1/2020

Login to get access

Abstract

Yellow fever (YF) is an acute viral disease, affecting humans and non-human primates (NHP), caused by the yellow fever virus (YFV). Despite the existence of a safe vaccine, YF continues to cause morbidity and mortality in thousands of people in Africa and South America. Since 2016, massive YF outbreaks have taken place in Brazil, reaching YF–free zones, causing thousands of deaths of humans and NHP. Here we reviewed the main epidemiological aspects, new clinical findings in humans, and issues regarding YFV infection in vectors and NHP in Brazil. The 2016–2019 YF epidemics have been considered the most significant outbreaks of the last 70 years in the country, and the number of human cases was 2.8 times higher than total cases in the previous 36 years. A new YFV lineage was associated with the recent outbreaks, with persistent circulation in Southeast Brazil until 2019. Due to the high number of infected patients, it was possible to evaluate severity and death predictors and new clinical features of YF. Haemagogus janthinomys and Haemagogus leucocelaenus were considered the primary vectors during the outbreaks, and no human case suggested the occurrence of the urban transmission cycle. YFV was detected in a variety of NHP specimens presenting viscerotropic disease, similar to that described experimentally. Further studies regarding NHP sensitivity to YFV, YF pathogenesis, and the duration of the immune response in NHP could contribute to YF surveillance, control, and future strategies for NHP conservation.
Literature
1.
2.
3.
Maguire HCF, Heymann DL. Yellow fever in Africa. BMJ. 2016:i3764.
4.
5.
6.
7.
Hanley KA, Monath TP, Weaver SC, Rossi SL, Richman RL, Vasilakis N. Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus. Infect Genet Evol. 2013;19:292–311.PubMedCrossRef
8.
Klitting R, Gould E, Paupy C, de Lamballerie X. What Does the Future Hold for Yellow Fever Virus? (I). Genes (Basel). 2018;9:291.CrossRef
9.
Moreno ES, Spinola R, Tengan CH, Brasil RA, Siciliano MM, Coimbra TLM, et al. Epizootias de febre amarela em primatas não humanos no estado de São Paulo, Brasil, 2008-2009. Rev Inst Med Trop Sao Paulo. 2013;55:45–50.PubMedCrossRef
10.
11.
Lindenbach BD, Murray CL, Thiel HJ, Rice CM. Flaviviridae. In: Knipe DM, Howley PM, editors. Fields Virol; 2013.
12.
Douam F, Ploss A. Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe. Trends Microbiol. 2018;XX:1–16.
13.
14.
Espinoza Villar JC, Ronchail J, Guyot JL, Cochonneau G, Naziano F, Lavado W, et al. Spatio-temporal rainfall variability in the Amazon basin countries (Brazil, Peru, Bolivia, Colombia, and Ecuador). Int J Climatol. 2009;29:1574–94.CrossRef
15.
Roig C, Miret J, Rojas A, Guillén Y, Aria L, Mendoza L, et al. Estudio de Fiebre Amarilla en primates en áreas de brote de los departamentos de San Pedro y Central del Paraguay. Memorias Del Inst Investig en Ciencias la Salud. 2009;7:40–5.
16.
Bryant JE, Holmes EC, ADT Barrett. Out of Africa: A molecular perspective on the introduction of yellow fever virus into the Americas. PLoS Pathog. 2007;3(5):e75.PubMedPubMedCentralCrossRef
17.
Mir D, Delatorre E, Bonaldo M, Lourenço-De-Oliveira R, Vicente AC, Bello G. Phylodynamics of yellow fever virus in the Americas: new insights into the origin of the 2017 Brazilian outbreak. Sci Rep. 2017;7:1–9.CrossRef
18.
Vasconcelos PFC, Bryant JE, Travassos APA, Tesh RB, Rodrigues SG, Barrett ADT. Genetic divergence and dispersal of yellow fever virus. Emerg Infect Dis. 2004;10(9):1578.
19.
Bonaldo MC, Gómez MM, Dos Santos AAC, De Abreu FVS, Ferreira-de-Brito A, De Miranda RM, et al. Genome analysis of yellow fever virus of the ongoing outbreak in Brazil reveals polymorphisms. Mem Inst Oswaldo Cruz. 2017;112:447–51.PubMedPubMedCentralCrossRef
20.
Cunha MS, da Costa AC, de Azevedo Fernandes NCC, Guerra JM, dos Santos FCP, Nogueira JS, et al. Epizootics due to yellow fever virus in São Paulo state, Brazil: viral dissemination to new areas (2016–2017). Sci Rep. 2019;9:1–13.CrossRef
21.
Faria NR, Kraemer MUG, Hill SC, De Jesus JG, Aguiar RS, Iani FCM, et al. Genomic and epidemiological monitoring of yellow fever virus transmission potential. Science. 2018;361:894–9.
22.
Gómez MM, de Abreu FVS, Dos Santos AAC, de Mello IS, Santos MP, Ribeiro IP, et al. Genomic and structural features of the yellow fever virus from the 2016-2017 Brazilian outbreak. J Gen Virol. 2018;99:536–48.PubMedCrossRef
23.
Quaresma JAS, Pagliari C, Medeiros DBA, Duarte MIS, Vasconcelos PFC. Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever. Rev Med Virol. 2013;23:305–18.PubMedCrossRef
24.
Tuboi SH, Costa ZGA,Vasconcelos PFC, Hatch D. Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002. Trans R Soc Trop Med Hyg. 2007;101:169–75.PubMedCrossRef
25.
Ho Y-L, Joelsons D, Leite GFC, Malbouisson LMS, Song ATW, Perondi B, et al. Severe yellow fever in Brazil: clinical characteristics and management. J Travel Med. 2019.
26.
Ribeiro AF, Cavalin RF, Suleiman JMAH, Da Costa JA, De Vasconcelos MJ, Málaque CMSA, et al. Yellow fever: Factors associated with death in a hospital of reference in infectious diseases, São Paulo, Brazil, 2018. Am J Trop Med Hyg. 2019;101(1):180–88.PubMedCrossRefPubMedCentral
27.
Kallas EG, D’Elia Zanella LGFAB, Moreira CHV, Buccheri R, Diniz GBF, Castiñeiras ACP, et al. Predictors of mortality in patients with yellow fever: an observational cohort study. Lancet Infect Dis. 2019;19(7);750–58.PubMedCrossRef
28.
Casadio LVB, Salles APM, Malta FDM, Leite GF, Ho YL, Gomes-Gouvêa MS, et al. Lipase and factor V (but not viral load) are prognostic factors for the evolution of severe yellow fever cases. Mem Inst Oswaldo Cruz. 2019;114:e190033.
29.
Marinho PES, Alvarenga PPM, Crispim APC, TMS C, Alvarenga AM, Bechler IM, et al. Wild-Type Yellow Fever Virus RNA in Cerebrospinal Fluid of Child. Emerg Infect Dis. 2019;25(8):1567.PubMedPubMedCentralCrossRef
30.
Barbosa CM, Di Paola N, Cunha MP, Rodrigues-Jesus MJ, Araujo DB, Silveira VB, et al. Yellow fever virus RNA in urine and semen of convalescent patient, Brazil. Emerg Infect Dis. 2018;24(1):176.PubMedCentralCrossRef
31.
Denis B, Chirio D, Ponscarme D, Brichler S, De Verdière NC, Simon F, et al. Hepatitis rebound after infection with yellow fever virus. Emerg Infect Dis. 2019;25(6):1248.
32.
33.
34.
Favoretto S, Araujo D, Oliveira D, Duarte N, Mesquita F, Zanotto P, et al. First detection of Zika virus in neotropical primates in Brazil: a possible new reservoir. bioRxiv. 2016.
35.
Terzian ACB, Zini N, Sacchetto L, Rocha RF, Parra MCP, Del Sarto JL, et al. Evidence of natural Zika virus infection in neotropical non-human primates in Brazil. Sci Rep. 2018;8(1):16034.
36.
37.
38.
39.
40.
41.
Collaborative group for studies on yellow fever vaccines. Duration of post-vaccination immunity against yellow fever in adults. Vaccine. 2014;32(39):4977–84.
42.
Campi-Azevedo AC, Costa-Pereira C, Antonelli LR, Fonseca CT, Teixeira-Carvalho A, Villela-Rezende G, et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Hum Vaccines Immunother. 2016;12:491–502.CrossRef
43.
Costa-Pereira C, Campi-Azevedo AC, Coelho-Dos-Reis JG, Peruhype-Magalhaes V, Araujo MSS. Do Vale Antonelli LR, et al. Multi-parameter approach to evaluate the timing of memory status after 17DD-YF primary vaccination. PLoS Negl Trop Dis. 2018;12:e0006462.PubMedPubMedCentralCrossRef
44.
45.
46.
47.
Selemane I. Epidemiological monitoring of the last outbreak of yellow fever in Brazil – an outlook from Portugal. Travel Med Infect Dis. 2019;28:46–51.PubMedCrossRef
48.
49.
Soper FL. Yellow Fever in the Americas, 1938–1942. Febre Amarela Panam. 1938;a:1942.
50.
51.
Soper FL, Penna H, Cardoso E, Serafim J Jr, Frobisher M Jr, Pinheiro J. Yellow fever without Aedes aegypti. Study of a rural epidemic in the Valle do Chanaan, Espirito Santo, Brazil, 1932. Am Soc Trop Med Hyg. 1933;18:555–87.CrossRef
52.
53.
Delatorre E, de Abreu FVS, Ribeiro IP, Gómez MM, dos Santos AAC, Ferreira-de-Brito A, et al. Distinct YFV lineages co-circulated in the Central-Western and southeastern Brazilian regions from 2015 to 2018. Front Microbiol. 2019;10:1–12.CrossRef
54.
Rezende IMD, Sacchetto L, Munhoz de Mello É, Alves PA, Iani FCM, Adelino TÉR, et al. Persistence of yellow fever virus outside the Amazon Basin, causing epidemics in Southeast Brazil, from 2016 to 2018. PLoS Negl Trop Dis. 2018;12(6):e0006538.PubMedPubMedCentralCrossRef
55.
56.
57.
de Abreu FVS, Delatorre E, Dos Santos AAC, Ferreira-de-Brito A, de Castro MG, Ribeiro IP, et al. Combination of surveillance tools reveals that yellow fever virus can remain in the same Atlantic Forest area at least for three transmission seasons. Mem Inst Oswaldo Cruz. 2019;114:e190076.PubMedPubMedCentralCrossRef
58.
59.
QGIS Development Team. Welcome to the QGIS project! Qgis. 2016.
60.
61.
62.
63.
64.
65.
66.
67.
68.
SES-SC. Boletim Epidemiológico da Febre Amarela n° 10/2019–29 de junho de 2019 Período de monitoramento (julho/2018 a junho/2019) [Internet]. Secr. Estado da Saúde - Gov. St. Catarina. 2018 [cited 2019 Jun 27]:1–7. Available from: Boletim Epidemiológico da Febre Amarela n° 10/2019–29 de junho de 2019%0APeríodo de monitoramento (julho/2018 a junho/2019).
69.
70.
71.
72.
73.
74.
Germain M, Mouchet J, Cordellier R, Chippaux A, Cornet M, Herve JP, et al. Épidémiologie de la fièvre jaune en Afrique. Med Mal Infect. 1978:69–77.CrossRef
75.
Abreu FVS, Ribeiro IP, Ferreira-de-Brito A, dos SAAC, de Miranda RM, de S BI, et al. Haemagogus leucocelaenus and Haemagogus janthinomys are the primary vectors in the major yellow fever outbreak in Brazil, 2016–2018. Emerg Microbes Infect. 2019;8:218–31.
76.
Cardoso JC, de Almeida MAB, dos Santos E, da Fonseca DF, Sallum MAM, Noll CA, et al. Yellow fever virus in Haemagogus leucocelaenus and Aedes serratus mosquitoes, southern Brazil, 2008. Emerg Infect Dis. 2010;16:1918–24.
77.
Couto-Lima D, Madec Y, Bersot MI, Campos SS, de Albuquerque MM, Dos Santos FB, et al. Potential risk of re-emergence of urban transmission of Yellow Fever virus in Brazil facilitated by competent Aedes populations. Sci Rep. 2017;7:1–12.
78.
Monath TP. Yellow fever. In: Monath TP, editor. Arboviruses Ecol Epidemiol. Boca Raton: CRC Press; 1989. p. 139–231.
79.
Whitman L, Antunes PCA. The transmission of two strains of jungle yellow fever virus by Aedes aegypti. Am J Trop Med. 1938:1(2):135–47.CrossRef
80.
Alencar J, Lorosa ES, Dégallier N, Serra-Freire NM, Pacheco JB, Guimarães AÉ. Feeding patterns of Haemagogus janthinomys (Diptera: Culicidae) in different regions of Brazil. J Med Entomol. 2006;42(6):981–85.PubMedCrossRef
81.
82.
Degallier N, da Rosa APA T, Herve JP. A comparative study of yellow fever in Africa and South America. Cienc Cult. 1992;44:143–51.
83.
Alencar J, de Mello CF, Barbosa LS, Gil-Santana HR, de A MD, Marcondes CB, et al. Diversity of yellow fever mosquito vectors in the Atlantic forest of Rio de Janeiro, Brazil. Rev Soc Bras Med Trop. 2016;49:351–6.PubMedCrossRef
84.
Forattini OP. Culicidologia Médica - Identificação, biologia e epidemiologia. Culicidologia Médica. 2002.
85.
Marcondes C, Alencar J. Revisão de mosquitos Haemagogus Williston (Diptera: Culicidae) do Brasil. Rev Biomed. 2010.
86.
87.
Hervé J-P. Travassos da Rosa APA. Ecologia da febre amarela no Brasil. Rev da Fund SESP, Rio Janeiro. 1983;28(1):11–9.
88.
Gomes AC, Torres MAN T, Ferri L, da Costas FR, da Silva AM. Encontro de Haemagogus (Conopostegus) leucocelaenus (Diptera: Culicidae), no Município de Porto Alegre, Estado do Rio Grande do Sul. Rev Soc Bras Med Trop. 2007;40:487–8.
89.
Possas C, Lourenço-de-Oliveira R, Tauil PL, Pinheiro FP, Pissinatti A, da Cunha RV, et al. Yellow fever outbreak in Brazil: the puzzle of rapid viral spread and challenges for immunisation. Mem Inst Oswaldo Cruz. 2018;113:e180278.
90.
Causey OR, Kumm HW, Laemmert HW. Dispersion of forest mosquitoes in Brazil; further studies. Am J Trop Med Hyg. 1950;30:301–12.PubMedCrossRef
91.
Mucci LF, Medeiros-Sousa AR, Ceretti-Júnior W, Fernandes A, Camargo AA, Evangelista E, et al. Haemagogus leucocelaenus and other mosquitoes potentially associated with sylvatic yellow fever in Cantareira State Park in the São Paulo metropolitan area, Brazil. J Am Mosq Control Assoc. 2016;32:329–32.PubMedCrossRef
92.
Pinheiro GG, Rocha MN, de Oliveira MA, Moreira LA, Filho JDA. Detection of yellow fever virus in sylvatic mosquitoes during disease outbreaks of 2017-2018 in Minas Gerais state, Brazil. Insects. 2019;10:E136.PubMedCrossRef
93.
Pereira dos Santos T, Roiz D, Santos de Abreu FV, Luz SLB, Santalucia M, Jiolle D, et al. Potential of Aedes albopictus as a bridge vector for enzootic pathogens at the urban-forest interface in Brazil. Emerg Microbes Infect. Springer US; 2018;7(1):1-8.CrossRef
94.
Miller BR, Ballinger ME. Aedes albopictus mosquitoes introduced into Brazil: vector competence for yellow fever and dengue viruses. Trans R Soc Trop Med Hyg. 1988;82:476–7.PubMedCrossRef
95.
Massad E, FAB C, Burattini MN, Lopez LF. The risk of yellow fever in a dengue-infested area. Trans R Soc Trop Med Hyg. 2001;95(4):370–74.PubMedCrossRef
96.
Johnson BW, Chambers TV, Crabtree MB, Filippis AMB, Vilarinhos PTR, Resende MC, et al. Vector competence of Brazilian Aedes aegypti and Ae. Albopictus for a Brazilian yellow fever virus isolate. Trans R Soc Trop Med Hyg. 2002;96:611–3.PubMedCrossRef
97.
98.
Lourenço-de-Oliveira R, Vazeille M, De Filippis AMB, Failloux AB. Oral susceptibility to yellow fever virus of Aedes aegypti from Brazil. Mem Inst Oswaldo Cruz. 2002;97:437–9.PubMedCrossRef
99.
Lourenço-de-Oliveira R, Vazeille M, de Filippis AMB, Failloux AB. Aedes aegypti in Brazil: genetically differentiated populations with high susceptibility to dengue and yellow fever viruses. Trans R Soc Trop Med Hyg. 2004;98:43–54.PubMedCrossRef
100.
Mittermeier, RA; Rylands, AB; Wilson, DE (Chief Eds.): Handbook of the Mammals of the World, vol. 3. Primates, Lynx Edicions, Barcelona. 2013:951.
101.
102.
Paglia AP, Fonseca GAB, Rylands AB, Herrmann G, Aguiar LMS, Chiarello AG, et al. Lista anotada dos mamíferos do Brasil Occas. Pap. Conserv. Biol. 2nd. Arlington, VA: Conservation International; 2012.
103.
Bicca-Marques JC, de Freitas DS. The role of monkeys, mosquitoes, and humans in the occurrence of a yellow fever outbreak in a fragmented landscape in South Brazil: protecting howler monkeys is a matter of public health. Trop Conserv Sci. 2010;3(1):78–89.CrossRef
104.
Duarte MHL, Goulart VDLR, Young RJ. Designing laboratory marmoset housing: what can we learn from urban marmosets? Appl Anim Behav Sci. Elsevier; 2012;137:127–136.CrossRef
105.
Teixeira B, Hirsch A, Goulart VDLR, Passos L, Teixeira CP, James P, et al. Good neighbours: distribution of black-tufted marmoset (Callithrix penicillata) in an urban environment. Wildl Res. 2015;42:579–89.
106.
Daviews CR, Ayres JM, Dye C, Deane LM. Malaria infection rate of Amazonian primates increases with body weight and group size. Funct Ecol. 1991:655–62.CrossRef
107.
Neville MK, Glander KE, Braza F, Rylands AB. The howling monkeys, genus Alouatta. In: Mittermeier, R. A., Rylands, A. B., Coimbra-Filho, A. F. and Fonseca GAB, editor. Ecol Behav Neotrop Primates, vol 2. Washington, DC: World Wildlife Fundation; 1988:348–453.
108.
de Thoisy B, Richard-Hansen C. Diet and social behaviour changes in a red howler monkey (Alouatta seniculus) troop in a highly degraded rain forest. Folia Primatol. 1997;68:357–61.
109.
Woodall JP, Dykes JRW, Williams MC. The reaction of a species of Colobus monkey to inoculation with yellow fever virus. Ann Trop Med Parasitol. 1968;62:528–35.CrossRef
110.
Taufflieb R, Robin Y, Cornet M. Le virus amaril et la faune sauvage en Afrique. Cahiers. ORSTOM Série Entomol Médicale Parasitol. 1971;9:351–71.
111.
Taylor RM, Haseeb MA, Work TH. A regional reconnaissance on yellow fever in the Sudan. With special reference to primate hosts. Bull World Health Organ. 1955;12:711–25.PubMedPubMedCentral
112.
Davis NC. Susceptibility of capuchin (Cebus) monkeys to yellow fever virus. Am J Epidemiol. 1930;11:321–34.CrossRef
113.
114.
Davis NC. The transmission of yellow fever: experiments with the “woolly monkeys” (Lagothrix Lagotricha Humboldt), the “spider monkey” (Ateleus Ater F. Cuvier), and the “squirrel monkey” (Saimiri Scireus Linnaeus). J Exp Med. 1931;51:703–21.
115.
Holzmann I, Agostini I, Areta JI, Ferreyra H, Beldomenico P, di Bitetti MS. Impact of yellow fever outbreaks on two howler monkey species (Alouatta Guariba clamitans and A. caraya) in Misiones, Argentina. Am J Primatol. 2010;72:475–80.
116.
Ott-Joslin JE. Viral diseases in nonhuman primates. In: M F, editor. Zoo wild Anim Med. Philadelphia: W.B. Saunders; 1986:674–697.
117.
Burke AW. An Epidemic of Jungle Yellow Fever on the Planalto of Mato Grosso, Brazil. Am Soc Trop Med Hyg. 1937;s1–17:313–334.CrossRef
118.
Laemmert HW, Hughes TP, Causey OR. The Invasion of Small Forests by Yellow Fever Virus as Indicated by Immunity in Cebus Monkeys. Am Soc Trop Med Hyg. 1949;s1–29:555–565.CrossRef
119.
Laemmert Jr HW, Ferreira LC, Taylor RM. An epidemiological Study of jungle yellow fever in a endemic area in Brazil. Part II – Investigations of vertebrate hosts and arthropod vectors. Am Soc Trop Med Hyg. 1946;s1–26:23–69.
120.
Kumm HW, Laemmert Jr. HW. The Geographical Distribution of Immunity to Yellow Fever among the Primates of Brazil. Am Soc Trop Med Hyg. 1950;s1–30:733–748.
121.
Strier KB, Tabacow FP, de Possamai CB, Ferreira AIG, Nery MS, de Melo FR, et al. Status of the northern muriqui (Brachyteles hypoxanthus) in the time of yellow fever. Primates Springer Japan; 2019;60:21–28.PubMedCrossRef
122.
Laemmert HW, Kumm HW. The susceptibility of howler monkeys to yellow fever virus. Am J Trop Med Hyg. 1950;30(5).CrossRef
123.
Galindo P. Monkeys and yellow fever. In: Nonhum Primates Med Res. 3rd ed: Academic Press, Inc. 1973.
124.
De Thoisy B, Vogel I, Reynes JM, Pouliquen JF, Carme B, Kazanji M, et al. Health evaluation of translocated free-ranging primates in French Guiana. Am J Primatol. 2001;54:1–16.PubMedCrossRef
125.
Pinheiro FP, da Rosa APA T, da Rosa MAP T. An Epidemic of Yellow Fever in Central Brazil, 1972–1973. II. Ecological Studies. Am Soc Trop Med Hyg. 1981;30:204–11.CrossRef
126.
Agostini I, Holzmann I, Di Bitetti MS. Infant hybrids in a newly formed mixed-species group of howler monkeys (Alouatta guariba clamitans and Alouatta caraya) in northeastern Argentina. Primates. 2008;49:304–7.PubMedCrossRef
127.
Vargas-Mendez O, Elton NW. Naturally acquired yellow fever in wild monkeys of Costa Rica1. Am J Trop Med Hyg. 1953;2:850–63.PubMedCrossRef
128.
Collias N, Southwick C. A field study of population density and social organization in howling monkeys. Am Philos Soc. 1952;96:143–56.
129.
Auguste AJ, Lemey P, Bergren NA, Giambalvo D, Moncada M, Morón D, et al. Enzootic transmission of yellow fever virus. Venezuela Emerg Infect Dis. 2015;21:99–102.PubMedCrossRef
130.
Rifakis PM, Benitez JA, De-La-Paz-Pineda J, Rodriguez-Morales AJ. Epizootics of yellow fever in Venezuela (2004-2005): an emerging zoonotic disease. Ann N Y Acad Sci. 2006;1081:57–60.PubMedCrossRef
131.
De Almeida MAB, Dos Santos E, Da Cruz CJ, Da Fonseca DF, Noll CA, Silveira VR, et al. Yellow fever outbreak affecting Alouatta populations in southern Brazil (Rio Grande do Sul state), 2008-2009. Am J Primatol. 2012;74:68–76.PubMedCrossRef
132.
Sallis ESV, de Barros VLRS, Garmatz SL, Fighera RA, Graça DL. A case of yellow fever in a brown howler (Alouatta fusca) in southern Brazil. J Vet Diagn Investig. 2003;15:574–6.PubMedCrossRef
133.
Laemmert Jr HW, Ferreira LC. The Isolation Of Yellow Fever Virus From Wild-Caught Marmosets. Am Soc Trop Med Hyg. 1945;s1–25:231–232.CrossRef
134.
Bates BC. Territorial behavior in primates: a review of recent field studies. Primates. 1970;11(3):271-284.CrossRef
135.
Davis NC, Shannon RC. Studies on South American yellow fever III. Transmission of the virus to Brazilian monkeys preliminary observations. J Exp Med. 1929;4:81–5.PubMedPubMedCentralCrossRef
136.
de Abreu FVS, dos Santos E, Gomes MQ, Vargas WP, Oliveira Passos PH, Nunes e Silva C, et al. Capture of Alouatta guariba clamitans for the surveillance of sylvatic yellow fever and zoonotic malaria: Which is the best strategy in the tropical Atlantic Forest? Am J Primatol. 2019: e23000.
137.
Figueiredo PO, Silva ATS, Oliveira JS, Marinho PE, Rocha FT, Domingos GP, et al. Detection and molecular characterization of yellow fever virus, 2017. Brazil Ecohealth. 2018;15:864–70.PubMedCrossRef
138.
Fernandes NCC, Cunha MS, Guerra JM, Réssio RA, Cirqueira CS, S. DI, et al. Outbreak of yellow fever among nonhuman primates, Espirito Santo, Brazil, 2017. Emerg Infect Dis. 2017;23:2038–41.PubMedPubMedCentralCrossRef
139.
Leal SG, Romano APM, Monteiro RV, de Melo CB, Da C VPF, de Castro MB. Frequency of histopathological changes in howler monkeys (Alouatta sp.) naturally infected with yellow fever virus in Brazil. Rev Soc Bras Med Trop. 2016;49:29–33.PubMedCrossRef
140.
Stokes A, Bauer JH, Hudson NP. The transmission of yellow fever to Macacus rhesus. J Am Med Assoc. 1928;90:253–4.CrossRef
141.
Bearcroft WGC. The histopathology of the liver of yellow fever infected rhesus monkeys. J Pathol. 1957;LXXI:295–303.CrossRef
142.
Engelmann F, Josset L, Girke T, Park B, Barron A, Dewane J, et al. Pathophysiologic and Transcriptomic analyses of Viscerotropic yellow fever in a rhesus macaque model. PLoS Negl Trop Dis. 2014;8(11):e3295.PubMedPubMedCentralCrossRef
143.
Monath TP, Brinker KR, Chandler FW, Kemp GE, Cropp CB. Pathophysiologic Correlations in a Rhesus Monkey Model of Yellow Fever With Special Observations on the Acute Necrosis of B Cell Areas of Lymphoid Tissues. Am Soc Trop Med Hyg. 1981;30:431–43.CrossRef
Metadata
Title
Recent sylvatic yellow fever virus transmission in Brazil: the news from an old disease
Authors
Natalia Ingrid Oliveira Silva
Lívia Sacchetto
Izabela Maurício de Rezende
Giliane de Souza Trindade
Angelle Desiree LaBeaud
Benoit de Thoisy
Betânia Paiva Drumond
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2020
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-019-1277-7

Other articles of this Issue 1/2020

Virology Journal 1/2020 Go to the issue

Research

AIV polyantigen epitope expressed by recombinant baculovirus induces a systemic immune response in chicken and mouse models

Research

Viral metagenomics revealed diverse CRESS-DNA virus genomes in faeces of forest musk deer

Research

The recombinant pseudorabies virus expressing African swine fever virus CD2v protein is safe and effective in mice

Short report

Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID‐19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series

Research

Assessments of different inactivating reagents in formulating transmissible gastroenteritis virus vaccine

Author Correction

Author Correction: In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits